Please assess the completion status of the following clinical trial:

Trial Title: Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Group A (Bleeding patients)~  * Overt bleeding judged by the physician to require a reversal agent~ * Currently taking dabigatran etexilate~ * At least 18 years of age~ * Written informed consent~* Group B (Patients who are taking dabigatran who may not be bleeding, but do require an emergency surgery or procedure for a condition other than bleeding~  * Condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours.~ * Current treatment with dabigatran~ * At least 18 years of age~ * Written Informed consent.~Exclusion criteria:~* Group A (Bleeding Patients)~  * Patients with minor bleeds (epistaxis, hematuria) who can be managed with standard supportive care.~ * Patients with no clinical signs of bleeding~ * Contraindications to study medication including known hypersensitivity to the drug or its excipients.~* Group B (Patients who require emergency surgery or procedure)~  * A surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low.~ * Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- idarucizumab (Type: EXPERIMENTAL): idarucizumab Only 1 treatment, no placebo or comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).